News 2022-03-02
Porton Plans to Invest 420 million to Expand CDMO Production Capacity of Small Molecule API
March 1st, 2022, Chongqing · China – Porton Pharma Solutions Ltd. announced an investment of 420 million to expand CDMO Production Capacity of Small Molecule API in Porton Pharma (Jiangxi) Co., Ltd. which is mainly engaged in customized production of APIs, intermediates and starting materials.
This expansion project will add 2 production workshops, utilities workshop, comprehensive warehouses and other facilities, which total construction area is 31,270㎡. With an estimated new production capacity of 300 m3, it is planned to be completed and put into operation by the end of 2023. In the future, Porton will undertake more high value-added intermediates and API production projects, which will help further consolidate the company's comprehensive capabilities as an End-to-End CDMO service platform.
Others
More
News 2026-10-24
Porton Shared Complex Bioconjugate Development Strategies at the 17th World ADC San Diego
As a conference partner, Porton contributed a scientific presentation and poster addressing the technical challenges of developing ADCs and emerging bioconjugates.
News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.
